A Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Profile of AZ-009 in Subjects With Established Parkinson's Disease
Latest Information Update: 02 Jun 2022
Price :
$35 *
At a glance
- Drugs Apomorphine (Primary)
- Indications Parkinson's disease
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Alexza Pharmaceuticals
- 23 Oct 2020 Status changed from recruiting to completed.
- 16 Sep 2020 Results (n=24) presented at the 24th International Congress of Parkinson's Disease and Movement Disorders
- 01 Mar 2020 Planned primary completion date changed from 15 Feb 2020 to 15 Mar 2020.